Antengene Corporation Limited announced that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting to be held in San Diego from November 1-5, 2023.
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting Read More »
Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the Taiwan Food and Drug Administration has approved the New Drug Application for XERAVA® for the treatment of complicated intra-abdominal infections.
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced the results from its annual meeting of shareholders.
Akeso, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for AK117, a next generation CD47 monoclonal antibody in combination with azacitidine for treatment of patients with newly diagnosed higher-risk myelodysplastic syndromes.
Basilea Pharmaceutica Ltd, Allschwil announced that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine, one of the world’s leading peer-reviewed medical journals.
BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity’s BC3402, a monoclonal antibody targeting the T cell immunoglobulin and mucin domain-containing protein 3, also known as TIM-3, in combination with AstraZeneca’s anti-PD-L1 mAb IMFINZI for the treatment of advanced hepatocellular carcinoma.
BrainStorm Cell Therapeutics Inc. announced the outcome of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting to review the Biologics License Application for NurOwn®, an investigational mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis.
Geneos Therapeutics announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million.
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million Read More »
FDA Quality and Regulatory Consultants (FDAQRC) is pleased to announce the promotion of six employees during the third quarter.
As MSLs take on greater roles in healthcare, standardization is crucial to fostering trust.
Why Medical Science Liaisons Should Earn Board Certification Read More »
